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ABSTRACT 
Background: The burden of tuberculosis in Nigeria is the third highest in the world. The 
data from the TB programme of the States’ ministries of health are usually unpublished 
which possibly contributes to the prevailing ignorance and poor attitude of Nigerians to 
the disease.  
Objectives: To determine the trends of TB burden and treatment outcome in Enugu state; 
and compare the State’s disease burden to that of the Nation.   
Methods: The study was a quantitative action research of secondary data from the TB 
control programme, Ministry of health, Enugu state, the National annual report of 2008, 
and WHO TB database within the 10 year period of 2000-2009. Data analysis and 
presentations were descriptive.  
Results: The modal age group for new ss+ PTB cases in Enugu state was 25-34 years 
.The number of female cases was higher than males within the 0-14 year ager group. The 
annual number of all TB cases showed a raising trend from 914 cases in the year 2000 to 
1684 in 2009; but, the reported new ss+ PTB cases fluctuated in a wave-like pattern. The 
median number of extra-pulmonary TB cases for 2005-2009 was 150 cases while that for 
the period 2000-2004 was 36 – a four fold increase.  
The mean prevalence of HIV for all TB cases and new ss+ PTB were 34.4% and 30.7% 
respectively for the period 2008-2009. Also, the median treatment success rate was 82% 
(range: 78-85). 
On the average, Enugu State contributed 1.77% of all TB cases and 2.10% of new ss+ 
PTB to the national annual TB register and a TB case reported in Enugu state was more 
likely to be a new ss+ PTB when compared to the whole nation [P < 0.001, OR = 1.33 
(95% CI: 1.26, 1.40)] 
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The possible impediments to TB control programme in the State include inadequate 
funds, ignorance and health seeking pattern of the residents, lack of confidence in the 
public health care delivery system, non-compliance of private medical practitioners to the 
approved TB treatment guidelines. 
Conclusion: Though the burden of TB in Enugu state had increased over the study 
period, the State’s contribution to the disease burden in Nigeria is low. Community 
participation in TB control and PPM, among other recommendations, will improve TB 
case detection and treatment in the State.  
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INTRODUCTION 
Tuberculosis(TB) is an infectious disease whose scourge has been with humans 
throughout known history.1 About one third of the over 6 billion world population is 
estimated to be infected with the disease causing organism, and the lifetime risk of 
developing the disease, for each person, can be over 10%.2 It is therefore a global 
pandemic whose impact on world development is well recognized which made the United 
Nations (UN) to define TB-specific indicators for monitoring her target of reversing the 
incidence of major diseases by the year 2015.3 Though TB is curable, about 4500 people 
die of the disease daily and it is noteworthy that most of these deaths occur in developing 
countries where poverty, malnutrition, and HIV/AIDS are also prevalent.4 In response to 
the huge burden of TB, a major effort towards global control of the disease was initiated 
through the widespread implementation of the DOTS strategy, and this effort is being 
consolidated and enhanced through the Stop TB Strategy.5 The four main targets of this 
global control are: the fall of TB incidence by the year 2015; the reduction of TB 
prevalence and death by half by 2015 when compared to their levels in 1990; the 
detection and treatment of at least 70% of the estimated incident cases in DOTS 
programme; and finally, the successful treatment of at least 85% of incident smear-
positive cases.6  
The UN has described the prevalence and deaths from TB as better sensitive indicators of 
the changing burden of disease3 therefore, the global TB control efforts could be viewed 
as successful because the recent WHO report has predicted that TB prevalence and deaths 
would be halved in three out of the six WHO regions by the target year.6 However, Africa 
in general and Nigeria in particular may not be sharing in the global success story – 
Africa contributed 33% of estimated prevalent cases in 2007 while Nigeria contributed 
460,000 cases thereby ranking 4th in the global list of high disease burden countries.6 
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Nigeria is a very populous nation that is divided into several administrative units (States) 
with varying ethnicity, socio-economic and health indices. How much of the reported 
national TB burden that is contributed by each State is rarely known to the public, and 
this may be contributing to the prevailing inappropriate care seeking behaviour and poor 
awareness of the disease in Nigeria.7 
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STUDY JUSTIFICATION  
The ultimate target of the Stop TB partnership is to eliminate TB as a public health 
problem (less than 1 case per million population) by the year 2050.8 On the other hand, 
Nigeria is a setting where several health care options (medical pluralism)9 including 
orthodox medicine (public, private, or drug stores), traditional medicine, spiritual healers 
etc; the public health facilities within which the TB control programme operates is 
“distanced” from the people and are often not the first choice during health seeking 
decisions. Therefore, for the above target to be achievable in Nigeria using the current 
passive detection strategy, the people at the community level should be empowered to 
partner with the TB control objectives through adequate knowledge of the growing 
burden of the disease and the accessible potentials for cure. As earlier stated, data on TB 
burden from the States of Nigeria are not published and Enugu state is not an exemption. 
The TB data reposited with the various States’ ministries of health appear to be meant 
only for generating national estimates and reports. It is argued that if information on the 
magnitude of TB burden generated from DOTS centers are fed back to the people through 
the existing community structures such as women meetings etc, detection rate of TB in 
Nigeria will increase remarkably and the reported TB burden may approach the true 
population figures. This argument is supported by a recent study which showed that the 
average delay by patients in southern Nigeria (including Enugu state) before presenting to 
DOTS centers was 3 months, and the main reason for the poor use of DOTS facilities was 
ignorance.7  
Furthermore, TB is linked to poverty and HIV/AIDS. Residents of Enugu state are 
predominantly poor and the HIV prevalence in the State is the highest among the five 
South-eastern States of Nigeria.10 It follows therefore, that the reported TB burden in the 
State may contribute significantly to the national figures, otherwise gross low detection of 
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the disease could be suspected. So, it became important to study the changing burden of 
TB in the State in relation to the national burden. Also, in other to protect the vulnerable 
population of the State from tuberculosis, as stipulated in the Stop TB Strategy, the State’s 
ministry of health would be encouraged to disseminate the study results and also adapt 
them for use in community partnership towards TB control. 
 
 
 
 
  5 
 
 
AIM AND OBJECTIVES 
Aim 
• To determine the trends in the prevalence, incidence, and treatment outcome of  
tuberculosis in Enugu state, South-eastern  Nigeria from 2000 to 2009 
Specific objectives  
• To determine the trends of the reported annual TB prevalence, TB incidence, and 
new smear positive PTB in Enugu state of Nigeria, over a ten year period of 2000 
to 2009 
• To determine the treatment outcome of cohorts of incident smear-positive TB in 
Enugu state of Nigeria, within the same period. 
• To compare trends of the reported TB prevalence and incident smear positive PTB 
in Enugu state from 2004 to 2008, to the Nigerian national trends over the same 
period. 
• To determine the possible factors militating against TB control in Enugu state and 
proffer recommendations   
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LITERATURE REVIEW 
Aetiology of TB 
TB is caused by the infection with tubercle bacilli - a generic name that incorporates an 
expanding list of Mycobacterium species collectively called Mycobacterium tuberculosis 
complex. Members of this group are: Mycobacterium tuberculosis, M. bovis, M. 
africanum, M. microti, M. canetti, M. caprae, and M. pinnipedi.11;12 They are generally 
facultative intracellular (phagocytes) pathogens which may be related to their long period 
of persistence in individuals with latent TB.12 Also, they are obligate aerobes therefore; 
grow better in oxygen rich tissues such as the lungs which may explain why majority of 
the disease involves the lungs. However, despite their high degree of DNA similarity, M. 
tuberculosis is the major cause of human tuberculosis.13 Molecular typing of M. 
tuberculosis complex among TB patients in Nigeria showed that majority of the disease 
was caused by M. tuberculosis followed by M. africanum, while M. bovis contributed the 
least.14   
History of TB 
TB seams to have been a global public health problem for many centuries as shown by its 
global afflictions and impacts.1 Despite the lack of archaeological evidence, the causative 
organism is hypothesized to have originated from East Africa.1 Nevertheless, the 
identification of classical skeletal features of the disease,15 and the amplification of M. 
tuberculosis DNA16 in Egyptian mummies are pointers to the possible devastating impact 
of the disease in ancient Africa.  
The isolation of the tubercle bacillus in 1882 by Robert Koch gave hope to the control of 
an almost evasive disease. Furthermore, the development of streptomycin, isoniazid, and 
rifampicin in the mid 20th century introduced a new and effective regime for treatment of 
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TB; prior to then, several treatment strategies with unconfirmed effectiveness such as rest 
(in sanatorium), exercise, and pulmonary collapse strategies, had been employed.1;17  
The only available vaccine for TB is Bacille Calmette Guerin (BCG). It is made of live 
attenuated M. bovis, and was first used in 1921.18 Incidentally the vaccine neither 
prevents primary infection nor the reactivation of latent pulmonary infection which makes 
it useless for the much needed primary prevention of TB.19  
Furthermore, the DOTS was introduced in Nigeria in 1993 by the German 
tuberculosis/leprosy Relief Agency (GLRA), and implementation was expanded to all 
States of the Federation in 2004.20  
Transmission of TB 
TB is a chronic infection with predilection for the human lungs (pulmonary TB) but, it 
can affect any other organ of body (extra-pulmonary TB).20 The causative organisms are 
transmitted through the inhalation of airborne droplet nuclei generated from individuals 
with the pulmonary disease.21 Following the infection, any of these outcomes may result 
thus: the bacilli may be killed by the host immune system; they may proliferate and cause 
primary TB; they may be dormant and remain asymptomatic (latent infection); or they 
may be reactivated after a period of latency.22 It is estimated that about 5-10% of persons 
with latent infection will develop TB during their lifetime but the risk is higher among 
children and the immunocompromised such as HIV/AIDS.21 Also, an average of 10-15 
persons are estimated to contract the infection annually from one infectious pulmonary 
TB case.19  
A lot of host and environmental factors interact to predispose individuals to TB; the 
independent risk factors identified in West Africa include family history of TB, 
household crowding, male sex, HIV infection, smoking - the latter had a dose-response 
relationship with TB,23 and therefore should stimulate further studies. A related study in 
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Gambia had also identified ethnicity as a risk factor but explained that it could be due to 
the underlying environmental and behavioural factors.24 Furthermore, a recent study from 
Tanzania showed that though patients with prolonged duration of cough (two or more 
weeks) had a higher likelihood of being diagnosed with TB when compared to those with 
shorter duration of cough, the relationship was not significant [OR = 1.6 (95% CI: 0.59, 
4.49)].25 In Nigeria, the inefficient health system is believed to be perpetuating the cycle 
of disease-poverty-disease of majority of Nigerian,26 and this theory definitely applies to 
TB.  
Diagnosis of TB  
TB can affect any organ of the body but the pulmonary TB especially the reactivated 
latent infection is of most public health concern because it is the major source of tubercle 
bacilli spread in the communities.19 Further reviews will therefore be restricted to PTB.   
Generally, the diagnosis of TB is based on “possible exposure, a typical disease history, 
suggestive clinical findings, typical radiological changes and positive bacteriological 
tests.”19 Sputum smear direct microscopy and conventional solid media culture are the 
most widely used laboratory diagnostic methods in the global TB control. However, most 
diagnoses of TB are based on the smear microscopy for acid-fast bacilli (AFB). The 
technique is fast, accessible, and specific but it is limited by its low and variable 
sensitivity and the inability to detect drug resistant bacilli.27 Because of the progressive 
improvement of the quality assurance programmes for smear microscopy, WHO has 
redefined a new sputum smear-positive PTB as the presence of single AFB in at least one 
sputum smear examination from a TB suspect.27 Likewise, the number of smears required 
for the diagnosis of PTB has been reduced to two.27 This decision considered the barriers 
of accessing TB control services in resource poor setting including laboratory workload, 
as well as the incremental diagnostic yield of 3 serial sputum specimens; and hoped that 
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the new policy would enhance case detection through improved “quality of service, 
decreased time for diagnosis and initiation of treatment and decreased patients drop out 
from the diagnostic pathway”.27 
The national tuberculosis programme in Nigeria relies on direct microscopy for diagnoses 
of PTB (Fig. 1), and is yet to adopt the new WHO policy on new smear positive PTB.28 
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Figure 1: A flow chart for the management of TB suspects in Nigeria.28 
  
 
 
Cough 2 weeks and more – collect 3 sputum specimens 
Sputum AFB microscopy 
AFB +, +, + 
AFB +, +, 0 
AFB +, +, sc 
AFB +, sc, 0 
AFB +, 0, 0 
AFB sc, 0, 0 
AFB 0, 0, 0 
Repeat 3 specimens 
Broad spectrum 
antibiotics (except 
Fluoroquinolones) for 
7 days and review 
after 2 weeks 
No improvement Improved 
No TB Repeat 3 specimens 
Medical 
Officer to 
decide on 
further action 
2 or more 
positive 
1 positive All negative 
1 or more 
positive 
All negative 
Yes TB 
Treat as TB 
No TB 
Refer to Medical Officer for 
further investigation 
No TB 
Medical 
Officer to 
decide on 
further 
action 
Key: 
+: - positive sputum result expressed in grades 1+, 2+ or 3+; 
Sc: - means a scanty positive sputum result;  
0: - a negative sputum result 
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Treatment of TB 
BCG vaccination and chemoprophylaxis are unsatisfactory TB control measures thereby 
leaving anti-tubercular (anti-TB) chemotherapy as the only option.29 The essential (first-
line) anti-TB drugs are isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E), 
and streptomycin (S).5 Their use in combinations (multi-drug therapy) is aimed at 
achieving cure without relapse, preventing death, impeding transmission by depleting 
infection source pool, and preventing the emergence and transmission of drug 
resistance.5;29 The fixed-dose combinations (FDCs) have equivalent efficacy to separate-
tablet combinations30 and are therefore preferred because of several advantages such as 
increased patient acceptance, discouragement of selective ingestion of the drugs and 
possible monotherapy, and prescription error.5 Other strategies introduced to improve TB 
treatment are the “patient kit” which ensures that the full treatment for a patient is 
available for the desired treatment duration; the “standard regimen” which introduced a 
standard (same) treatment for each patient registration group (category).5 
The standard therapies of TB are usually divided into 2 phases, an initial intensive phase 
followed be a continuation phase. For new patients, the regime (2HRZE/4HR) consists of 
an intensive phase of rifampicin, isoniazid, pyrazinamide, and ethambutol daily for 2 
months, and a continuation phase of rifampicin and isoniazid for a further 4 months, 
preferably daily or 3 times per week.5 Thrice weekly regime through out the course of the 
treatment is an acceptable alternative in non HIV-prevalent areas provided that treatment 
is directly observed.5 This therefore implies that Nigeria with an HIV/AIDS prevalence 
rate of 3.1% as at 2007,31 is not eligible to use this alternative regime. Furthermore, in 
settings with proven or unknown isoniazid resistance level, HRE instead of HR should be 
used at the continuation phase. The isoniazid resistance status (new cases) of Nigeria is 
assumed to be low. This is supported by a very small sample study from Jos, northern 
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Nigeria which did not identify isoniazid resistance in both new and follow-up cases.32 
Nevertheless, this report contrasts an earlier and equally small sample study from a 
similar region which reported an isoniazid resistance of 6.6% among new cases.33  
The DOTS in Nigeria uses 2HRZE/4HR or 2HRZE/6HE regimes for category 1 (new 
cases) – 6HE is self administered while 4HR therapy should be observed daily.28 For 
retreatment cases (category 2), the 2SRHZE/1RHZE/5RHE is used.28 The current WHO 
guideline recommends that all re-treatment cases undergo specimen culture and drug 
sensitivity testing (DST) for at least isoniazid and rifampicin before treatment if the Rapid 
molecular-based DST is available; otherwise standard empirical treatment (category 2) 
should be commenced and modified with the result of the conventional culture when 
available.5 The recommendation is in response to the report of the Global Project on Anti-
tuberculosis Drug Resistance Surveillance which showed a high global mean multi-drug 
resistance (MDR) of 15.3% [95% CI: 9.6-21.1] for previously treated cases when 
compared to 2.9% [95% CI: 2.2-3.6] among new cases.34 For the African region, the 
report showed a mean MDR of 1.5% [95% CI: 1.0-2.0] for new cases, and 5.8% [95% CI: 
3.9-7.7] for previously treated cases.34 This apparent low level of MDR-TB gives hope to 
the control of TB in this continent where poverty, hunger and HIV are endemic. 
However, the current workers’ manual used in Nigeria suggests that the WHO 
recommendation is only observed after treatment attempts at the category 2 level:  
“for patients who remain positive after category 2; continue RHE medication, 
inform the Local government TB supervisor (LGTBLS) or State TB control 
officer (STBLCO), and refer to medical officer for sputum culture, sensitivity 
test and appropriate treatment”28 
MDR-TB in Nigeria is apparently low - the estimate for 2007 was 1.8% for new cases 
and 9.4% for retreatment cases.6 Also, the study in Jos, reported an MDR of 4% among 
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new cases and 18% among the follow-up cases,32 while another study from a referral 
center in Ibadan, South-western Nigeria showed an MDR of 53.6% among new patients 
though over half of the cases were from the anti-retroviral clinic of the hospital.35 The 
obvious disparity between the two studies calls for a well designed nationwide survey to 
determine the true picture of anti-TB drug resistance.  
On the other hand, a study in Enugu, Nigeria among chronic TB patients referred by the 
national TB programme for category 2 related problems (failure, relapse, and returning 
defaulter with smear positive result), showed an MDR-TB of 72%, and poly-drug 
resistance of 25.6% while one patient each showed sensitivity to all drugs and isoniazid 
mono-resistance respectively.36 The study however has questionable internal validity 
because 33% of the study participants were excluded from analysis for various reasons.36 
Global burden of TB 6 
According to the WHO estimates for 2007,6 all incident cases of TB was 9.27 million as 
against 9.24 million in 2006, and 6.6 million in 1990. Most of the cases were from Asia 
(55%) and Africa (31%) while the least estimate was from the Americas (3%). Fifteen 
percent of the 9.27 million incident TB cases were co-infected with HIV and Africa 
contributed 79% of them. The high burden of TB in Asia and Africa is reflected on the 
WHO list of high TB burden countries which was topped by five countries from these 
regions.  
The estimated prevalent cases decreased from 13.9 million (210 per 100 000 population) 
in 2006, to 13.7 million (206 per 100 000 population) in 2007. Also, the estimated deaths 
from TB was 1.3 million among HIV-negative new TB cases (20 per 100 000 population) 
and 456 000 among new TB cases who were HIV-positive. Half a million TB cases were 
estimated to be MDR-TB in 2007; and by the end of 2008, 55 countries had reported 
extensively drug resistance TB (XDR-TB).  
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The case detection rate for new smear-positive cases for 2007 was 63% which was still 
lower than the DOTS target of 70%.  
National burden of TB  
In year 2007, Nigeria ranked fourth in the world and first in Africa with respect to the 
WHO estimated number of TB cases.6 Unfortunately, a 2008 report estimated the total 
TB cases in Nigeria as 922,575, and was ranked 3rd (behind India and China) on the list of 
high-burden countries.37 Furthermore, as at 2007, the WHO estimated that Nigeria had 
460,000 cases of all forms of TB, a TB prevalence of 521/100,000 population, 195,000 
new smear positive cases, incidence rate (all cases) of 311/100,000 per year, and 
incidence rate (new smear positive) of 131/100,000 per year.6 Further estimates include 
the prevalence of all forms of TB in HIV of 42/100,000, and a death rate of 93/100,000 
population per year (138,000 deaths/year).6   
However, the most recent national TB report20 showed that since 2002 when nation-wide 
expansion of DOTS started, only 455,552 of TB (all forms) have been registered; out of 
which 92.2% were new cases and 7.8% were retreatment cases. In 2008, a total of 90,311 
TB cases (92% new cases, 8% retreatment cases) were registered; notably, the sputum 
smear positive (ss+) cases contributed only 51% of the new cases. The reported new ss+ 
PTB cases represented only 30.5% of the estimated new ss+ for the year but, nearly 
doubled the detection rate of 16 % in 2002. The TB cases per State of the Federation for 
the same year, ranges from 721 cases in Ekiti to 9,864 cases in Lagos. The South-eastern 
zone to which Enugu state belongs, contributed the least (9%) cases (Fig. 2).   
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Figure 2: Annual TB cases by zones of Nigeria for year 200820             
 
National TB control programme of Nigeria20  
The national TB control activities in Nigeria are coordinated by the National tuberculosis 
and leprosy control programme (NTBLCP) which was launched in February 1991 under 
the department of Public health in the Federal ministry of health (FMOH). Its basic 
disease control strategy is the provision of free services to all patients identified with TB 
and its operations are guided by DOTS strategies and STOP TB Partnership initiatives.  
NTBLCP is structured along the three tiers of Nigerian government thus the Federal, 
State, and Local government areas (LGAs). Each level provides technical and 
management support to the one directly below it for instance, the Federal (National) 
programme supports the States’ TB control programme. Furthermore, the Federal level is 
also in charge of policy development, tertiary patient care, mobilization and development 
of human and material resource. The States’ TB programmes are responsible for 
coordinating TB control activities within the States, and provision of secondary patients’ 
care. The operational level of the national TB control programme is the LGAs and it is 
based on the principles of Primary health care (PHC). At least 2 health centers in each of 
the 774 LGAs in Nigeria have fully functional DOTS services.6 
18%
16%
20%9%
14%
23%
North-central
North-east
North-west
South-east
South-south
South-west 
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NTBLCP re-defined its strategies in 2006 and developed the following specific targets to 
be achieved by this year - 2010:    
• to detect 70% of the estimated smear positive TB 
• to successfully treat at least 85% of all detected TB cases 
• to ensure a minimum of 80% implementation rate of the programme’s activities 
by strengthening the technical and managerial capacity of the NTBLCP  
• to promote behavioural change in the community about TB such that 70% of adult 
population become aware of TB, its prevention, and the available free treatment as 
well as motivate the at risk groups to seek for immediate care  
• To reduce the incidence of TB among HIV patients by 25%  
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  METHODS   
Study setting 
The Federal Republic of Nigeria is made up of 36 States and these States are grouped into 
6 geo-political zones (Fig. 3). The States are further divided into smaller administrative 
units called LGAs and there is a total of 774 LGAs in the country. Nigeria is the most 
populous nation in Africa with a projected population of 149,229,090 million and 
population growth rate of 2.0% for year 2009.38 
Enugu state is one of the five States in the South-eastern zone of the country and it has an 
approximate land mass of 8,727.1 square kilometres (Fig. 3).39 The State capital is Enugu 
which is about 5 hours drive from Abuja the capital of Nigeria. The population of the 
State during the 2006 census was 3,257,298 million;40 however, with an estimated 
population growth rate of 2.28% ,26 the mid year population for 2010 would be 3,564,679. 
About 95% of the State’s population are ethnic Igbos and most of the existing 17 LGAs 
(Fig. 4) are rural with majority of the working population being farmers and petty traders 
26
 There is high fertility rate of 5.6, and the average family size is large with a range of 8 
to 12 persons per household.26 The life expectancy at birth is 51 years while the crude 
death rate is 18 per 1000 population.26 
The health care services in the State are delivered by private and government (public) 
health facilities. The latter includes the PHC facilities which are the responsibility of the 
LGAs, and the secondary care facilities which are managed by the State government. The 
government health care delivery services were rated as poor to fair by participants in a 
community survey.26 The private for-profit hospitals are mostly used by the community, 
while the PHC facilities which are the operational sites of the DOTS are the least 
patronized.26 Furthermore, the accessible recent National HIV sentinel survey showed 
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that Enugu state had an HIV/AIDS prevalence of 6.5% which was the highest in South-
eastern zone of the country.10 
The State has DOTS services in all the 17 LGAs of the State with a total of 95 functional 
DOTS and 30 microscopy centres.20 
  
Figure 3: Map of Federal Republic of Nigeria41  
Study design 
The study was a retrospective and quantitative research of unpublished secondary data 
from the TB control programme of the Ministry of health, Enugu state, Nigeria. The data 
source was the annual registration for TB from all the DOTS centers in the State. All 
available data on the number of TB cases of all categories registered annually (cohorts), 
the treatment outcome for the cohorts of new ss+ cases, the HIV prevalence per cohort of 
TB cases, as well as the age and sex distribution of incident ss+ cohorts for the period 
2000 to 2009, were included in the study. 
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Supplementary data for the national TB prevalence and new ss+ PTB for 2004-2008 were 
retrieved from the WHO online global TB database42 and the 2008 annual report of the 
NTBLCP.20 Because DOTS became nationwide in 2004, retrieval of national data was 
restricted to 2004. The 2009 data for the national TB was not available. 
Microsoft Excel 2003 computer software was used for data analysis. Data presentation 
was basically descriptive using tables and charts. However, Epi Info software version 
3.5.1 was used where applicable for inferential statistics at 95% confidence level and 
results were expressed using odd ratios (OR) and P-values. A P-value of less than 0.05 
was considered statistically significant.   
Possible impediments to TB control in Enugu state were identified through in-depth 
search for related literatures from the State and similar areas in Nigeria using the 
following online search engines African journal online, Google scholar, and PubMed. 
The e-library of the University of Bergen, and HINARI were used to download non-free 
articles.  
  
Figure 4: Map of Enugu state, South-eastern Nigeria43 
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Main definitions 
The definitions for different categories of TB patients and the treatment outcome by the 
national TB control of Nigeria are listed below (Tables 1 and 2):  
 
Table 1: Definitions for registered sputum smear positive TB patients in Nigeria.28 
Category Definition 
New case 
A patient who has never had treatment for TB or who has taken anti-TB 
drug for less than 4 weeks. 
Relapse 
A TB patient who previously received treatment and was declared cured 
or completed a full course of treatment and has once again developed 
sputum smear-positive TB 
Treatment 
failure 
A smear positive patient who while on treatment remained, or became 
smear positive again five months or later after starting treatment 
Treatment 
after default 
A TB patient who completed at least four weeks of Category 1 treatment 
and returned smear positive after at least 8 weeks of interruption of 
treatment 
Transfer in 
A TB patient already registered for treatment in one LGA/State who is 
transferred to another LGA/State where s/he continues treatment. 
Other 
All cases that do not fit the above definitions. This group includes:  
• Chronic cases – patients who remains smear positive after 
completing re-treatment regimen(cat 2) 
• A patient treated for TB outside the DOTS for more than four 
weeks and is smear-positive. 
• A patient diagnose as sputum smear negative TB after a cure or 
successful treatment   
• A patient who previously received treatment but outcome of 
treatment is un-known and now smear positive. 
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Table 2: Recording treatment outcome in smear-positive TB patients.28 
Cured 
A patient who was smear-positive at diagnosis, who completed 6 or 8 
months of treatment and who is smear-negative at the end of 6th or 7th 
month of treatment and on at least one previous occasion.  
Treatment 
completed 
Any patient who was smear-positive at diagnosis and who completed 
treatment but in whom smear examination results are not available at the 
end of treatment.  
Treatment 
failure 
Any patient who remains or becomes smear positive again at the end of 
fifth month or later during chemotherapy 
Treatment 
success 
the sum of patients cured and those who have completed treatment 
Died: 
Any patient who dies for any reason during the course of his/her 
chemotherapy. 
Defaulter: 
Any patient whose treatment was interrupted for 8 consecutive weeks or 
more after the date of the last attendance 
Transferred 
out a 
A patient who has been transferred to another treatment centre in another 
State and whose treatment result is not known.  
Note: ‘transferred out’ is not allowed within the same State; rather the 
patient can be referred to another LGA and his treatment outcome 
obtained during the quarterly review  meeting 
a The LGTBLS should obtain the outcome of every patient, including those that were 
referred to another health facility if possible.  
  
For the purpose of this study, a cohort means a group of TB patient diagnosed and 
registered for a specified one year period.44  
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RESULTS 
Gender and sex distribution of new ss+ PTB in Enugu state, 2005-2009 
The modal age group for new ss+ PTB cases in Enugu state was 25-34 years, followed by 
35-44 years while 0-14 years contributed the least (Table 3). In general, the total number 
of male cases registered for the five year period was higher than that of females. 
Nevertheless, below 15 years of age, the number of female cases was consistently higher 
than that of males through out the period. For the 15-24 year age group, the sex 
distribution pattern across the years was not consistent but the total number of female 
cases was still higher than that of males (Table 3, Fig. 4). For the remaining age groups, 
males contributed more cases per year than females except in 2009 when the male to 
female ratio was equal to a unity for the 55-64 year age group. Details of the sex and age 
distribution of new ss+ PTB cases in Enugu for 2005-2009 are shown in table 3. 
 
Figure 4: Sex and age groups of new ss+ PTB in Enugu state, 2005-2009 
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Table 3: Sex and age group distribution of new ss+ TB cases in Enugu state from 2005-2009 
Age group (years) 
Year Sex (M=male, F=female) 0-14 15-24 25-34 35-44 45-54 55-64 65+ 
Sub-total 
(%)* 
Total new ss+ 
TB 
M 0 52 131 90 87 43 34 437 (58.7) 
2005 
F 4 72 104 53 32 31 12 308 (41.3) 
745 
M 0 65 131 83 71 31 29 410 (56.8) 
2006 
F 8 74 107 65 33 20 5 312 (43.2) 
722 
M 4 62 110 88 78 54 30 426 (57.0) 
2007 
F 5 58 94 67 55 31 12 322 (43.0) 
748 
M 5 56 151 114 113 58 35 532 (55.1) 
2008 
F 8 65 141 69 79 46 25 433 (44.9) 
965 
M 8 69 130 109 81 57 24 478 (53.0) 
2009 
F 13 64 117 77 78 57 18 424 (47.0) 
902 
Total 
(%)** All sexes 
55 
(1.4) 
637 
(15.6) 
1216 
(29.8) 
815 
(20.0) 
707 
(17.3) 
428 
(10.5) 
224 
(5.5) 4082 4082 (100.0) 
 
* 
– denominator = total new ss+ TB for the corresponding year 
** 
– denominator = sum total of ss+ TB for 2005-2009  
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Trends of TB case finding in Enugu State, 2000-2009 
The reported annual number of all TB cases increased progressively from 914 cases in the 
year 2000 to 1684 in 2009 except in 2001 and 2004 when it (for each year) was less than 
that of the preceding year (Table 4). From 2004 to 2009, all cases of TB increased at a 
mean rate of 7.4% per annum (median 5.2%); the least annual increase of 1.2% occurred 
from 2004 to 2005 while the highest (16.1%) was reported from 2007 to 2008. 
The annual number of new ss+ PTB cases reported over the period was consistently 
above 500 (Fig. 5). The least (583) and highest (965) number of cases were reported in 
2001 and 2008 respectively (Table 4). Unlike the pattern of all TB cases which generally 
showed a raising trend, except the declines in 2001 and 2004, that of the new ss+ PTB 
cases appeared to follow an uneven wave-like pattern – one or two consecutive years of 
increased detection were followed by year(s) of declining detection of new ss+ PTB (Fig. 
6). The highest annual increase (29%) for new ss+ PTB was observed from 2007 to 2008. 
There were increased reports for all TB and smear -ve PTB cases in 2009 while registered 
new ss+ PTB cases showed a decline (Figs. 5, 6). On the other hand, the proportion of ss+ 
among the new PTB cases showed a consistent downward trend from 76% in 2005 to 
63% in 2009 (Fig. 7). Similar pattern also applied to the proportion of new ss+ of all TB 
cases (Fig. 7). 
After 2004, the number of reported extra-pulmonary TB cases increased markedly (Table 
4). The median number of extra-pulmonary TB cases detected over the five year period of 
2000-2004 was 36 while that for 2005-2009 was 150, which represents a 4 fold rise. 
The annual number of relapsed cases fluctuated across a narrow range of 28-63 over the 
period with a median of 43 cases (Table 4). Likewise, the median number of treatment 
failure cases was 8 (range: 4-17). The lowest treatment failure was reported in 2009 while 
the highest was in 2006. 
Table 4: Trends of TB case findings in Enugu state, 2000-2009  
New PTB Other PTB 
Year New ss+ 
(%) 
Smear negative 
(%) 
Relapsed 
(%) 
Failure 
(%) 
Return after 
default (%) Others 
Extra-pulmonary 
(%) 
All 
cases 
TB/ HIV 
(%)* 
2000 626 (68.5) 187 (20.5) 42 (4.6) 16 (1.8) 16 (1.8) 0 (0.0) 27 (3.0) 914 - 
2001 583 (67.2) 172 (19.8) 44 (5.1) 9 (1.0) 25 (2.8) 0 (0.0) 34 (3.9) 867 - 
2002 675 (62.9) 248 (23.1) 62 (5.8) 7 (0.7) 43 (4.0) 0 (0.0) 38 (3.5) 1073 - 
2003 769 (63.5) 285 (23.5) 60 (5.0) 7 (0.6) 45 (3.7) 0 (0.0) 46 (3.8) 1212 - 
2004 765 (64.5) 321 (27.0) 28 (2.4) 7 (0.6) 25 (2.1) 0 (0.0) 36 (3.0) 1187 - 
2005 745 (62.0) 235 (19.6) 34 (2.8) 11 (0.9) 36 (3.0) 0 (0.0) 126 (10.5) 1201 - 
2006 722 (57.6) 289 (23.1) 63 (5.0) 17 (1.4) 57 (4.6) 0 (0.0) 150 (12.0) 1253 - 
2007 748 (54.2) 342 (24.8) 52 (3.8) 10 (0.8) 38 (2.8) 13 (0.9) 177 (12.8) 1380 - 
2008 965 (60.2) 415 (25.9) 38 (2.4) 5 (0.3) 21 (1.3) 36 (2.3) 122 (7.6) 1602 411 (32.5) 
2009 902 (53.6) 515 (30.6) 39 (2.3) 4 (0.2) 16 (1.0) 0 (0.0) 164 (9.8) 1684 414 (36.2) 
 
*The denominator was the total number of all TB cases tested for HIV (1264 in 2008; 1144 in 2009) 
-  no data available 
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 Figure 5: Trends of PTB detection in Enugu state 
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Figure 6: Annual cumulative change in TB case detection in Enugu state  
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Figure 7: Trends of PTB detection in Enugu state, 2000-2009 
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 TB/HIV co-infection in Enugu state, 2008-2009 
The mean prevalence of HIV for all TB cases and new ss+ PTB were 34.4% and 30.7% 
respectively. Sixty eight percent of all TB cases were screened for HIV in 2009 which 
was significantly lower than the 79% screened in 2008 [P<0.001, OR = 0.57 (95% CI: 
0.48, 0.67)]. A similar significant difference was observed for new ss+ PTB cases (Table 
5). Though the prevalence of HIV among all TB cases and new ss+ PTB cases were 
higher in 2009, the values were not significantly different from those of the preceding 
year. Details of the available records on HIV screening and co-infection among TB cases 
in Enugu state are shown in table 5.  
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Table 5: HIV/TB co-infection in Enugu state, 2008-2009  
Parameters Year 2008 (%) Year 2009 (%) p-value OR (95% CI) 
All TB cases 
tested for HIV 1264 (78.9)
a 1144 (67.9)a < 0.001 0.57 (0.48-0.67) 
New ss+ tested 
for HIV 848 (87.9)
b 749 (83.0)b 0.003 0.68 (0.52-0.88) 
Total HIV+ve all 
TB cases 411 (32.5)
c 414 (36.2)c 0.059 1.18 (0.99-1.40) 
HIV+ve for new 
ss+ cases 
258 (30.4)d 232 (31.0)d 0.812 1.03 (0.82-1.28) 
 
a 
– denominator = all TB cases reported (table 4) 
b 
– denominator = new ss+ cases reported (table 4) 
c
 – denominator = all TB cases tested for HIV 
d
 – denominator = new ss+ cases tested for HIV 
 
 
Treatment outcome for new ss+ PTB in Enugu State, 2000-2008  
The summary of treatment outcomes (in percent) for the new ss+ PTB cohorts registered 
at the DOTS centers in Enugu from 2000 to 2008 is shown in table 6. The treatment 
success rate ranges from 78% in 2006 (and 2007) to 85% in 2001 with a median of 82%. 
Also, the median cure rate was 65% (range: 57-72). Both treatment success and cure rate 
showed remarkable increase in 2008 compared to the values of the preceding year. The 
difference between the treatment success rate and cure rate, which represents treatment 
completed, showed a near consistent downward trend from 2001 to 2008 (Fig. 8).  
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Table 6: Treatment outcome (percent) of new ss+ PTB cases in Enugu state 
Year Treatment 
success % 
Cured 
% 
Failure 
% 
Died 
% 
Defaulted 
% 
Transferred out 
% 
2000 84 68 2 5 7 3 
2001 85 57 2 4 7 3 
2002 83 58 0 6 8 3 
2003 83 60 0.6 5 9 3 
2004 82 66 1 6 9 1 
2005 80 63 0.9 5 12 2 
2006 78 65 1 7 10 3 
2007 78 65 8 1 9 3 
2008 82 72 5 0.8 11 2 
 
 
 
 
Figures 8: Trend of “Treatment completed” for new ss+ PTB cohorts in Enugu state 
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The trends of the proportion of new ss+ PTB cases that died, defaulted, or failed 
treatment are shown in figure 9. Generally, both treatment failure rates and death rates 
were consistently below 10% of the registered new ss+ PTB cases through out the period. 
From year 2006 to 2007, the death rates reduced remarkably while the failure rates 
increased by a similar margin; but in 2008, both parameters declined with varied 
magnitudes.  
On the other hand, the trend of default rates among cohorts of new ss+ PTB cases 
appeared to be in the upwards direction with occasional declines (Fig. 9). The median 
default rate was 9% (range 7-12). The highest default rate of 12% was recorded in 2005; 
incidentally, reduction in both failure and death rates also occurred in the same year. 
 
Fig. 9: Trends of unfavourable treatment outcome for new ss+ PTB cases in Enugu state  
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Comparison of the National and Enugu state trends of TB, 2004-2008 
From 2004 when DOTS services became nationwide in Nigeria, the percentage of all TB 
cases reported from Enugu state varied from 1.60% in 2007 to 1.97% in 2004 with a 
median of 1.77% (Table 7). Likewise, the median percentage of new ss+ PTB cases 
reported from Enugu state was 2.10%; the lowest value (1.70%) was in 2007 while the 
highest (2.27%). was in 2004. The percentages of both new ss+ PTB and all TB cases 
reported from Enugu increased in 2008 despite the progressive decline recorded from 
2005 to 2007 (Fig. 10). In all, a TB case reported in Enugu state in 2008, was 
significantly more likely to be a new ss+ PTB when compared to a national case report [P 
< 0.001, OR = 1.46 (95% CI: 1.32, 1.61)]. Likewise, for the whole period of 2004-2008, a 
TB case reported in Enugu state was also more likely to be a new ss+ PTB when 
compared to the whole nation [P < 0.001, OR = 1.33 (95% CI: 1.26, 1.40)]. 
 
Table 7: Percentages of reported National TB (all and new ss+) from Enugu state 
All TB New ss+ PTB 
Year 
Nigeria Enugu state Nigeria Enugu state 
2004 60,290 1,187 (1.97) 33,755 765 (2.27) 
2005 66,848 1,201 (1.80) 35,048 745 (2.13) 
2006 74,225 1,253 (1.69) 39,903 722 (1.81) 
2007 86,241 1,380 (1.60) 44,016 748 (1.70) 
2008 90,311 1,602 (1.77) 46,026 965 (2.10) 
Total (2004-08) 377,915 6,623 (1.75) 198,748 3945 (1.99) 
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Figure 10: Percentages of the National TB cases reported from Enugu state 
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Possible impediments to TB control in Enugu state 
The possible impediments to TB control in Enugu state of Nigeria are presented under 
common themes thus: Community related, Health system related, and Government related 
impediments.  
Community related impediments 
Ignorance and health seeking behaviour for TB: Participants (TB cases) in a study from 
Southern Nigeria,7 had identified ignorance as the major reason why TB suspects do not 
report to DOTS centers in the region. With the development of prolonged cough, most 
people in the community would first seek for care from a drug store and if the symptom 
persists, other forms of health care would be consulted singly or in combinations. This 
health seeking pattern was evident in the study where only 1.8% of the respondents 
presented straight to DOTS clinics without prior care while 48% were first treated at drug 
stores.7 It has been found that even among patients diagnosed of TB, some received 
treatment at drug stores or private health facilities and these forms of care have been 
shown to contribute majorly to treatment failures and MDR-TB among TB patients.36  
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Also, poor knowledge of the actual cause and transmission of TB may affect the disease 
control in the State. This may be supported by the report that TB patients who presented 
within four weeks of symptoms were more likely to know about the aetiology and mode 
of transmission of the disease unlike those who presented after 12 weeks of symptoms 
where over 90% were totally unaware of the disease.45   
Belief and attitude of the community to TB: In Igbo communities generally, it is widely 
held that TB is caused through witchcraft whereby an enemy poisons the food or drinks 
of another person. This belief may explain the health care seeking from herbalist and 
traditional healers after failure of treatment from the drug stores.7 Health seeking is often 
determined by people’s belief and perception of the disease, treatment experiences, and 
cost-benefit of the treatment among other considerations.9;46 The perceived poor attitude 
of health staff and low rating of the government (public) health facilities,7;26 within which 
DOTS is currently delivered in the study area suggest that DOTS centers may only be 
recommended when other ‘friendly’ alternative health care fail.   
A house-hold survey in South-eastern Nigeria (including Enugu state)47 showed that TB 
was ranked lowest among the 10 endemic tropical diseases, in terms of perception of the 
seriousness of disease occurrence and effects. This finding is unfortunate for TB control 
in Enugu state because the compliance of a community to any disease eradication 
programme may not be effective when the disease is viewed as a low-priority health 
problem.48    
Other community related factors: There are other factors that may be working against the 
TB control in the study area. Household over-crowding, which has been identified as an 
independent predisposing factor for TB control in West Africa,23 is rampant in Enugu 
where the house hold size in the community ranges from 8 to 12.26  
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Also, TB has strong association with HIV infection,2 and the prevalence of the latter in 
Enugu is the highest in South-eastern Nigeria.10 This is evident from the first part of this 
study’s results where the available two year data on TB/HIV co-infection showed a HIV 
prevalence of over 30%.  
Health system related impediments 
TB treatment by private for-profit health facilities: Communities in Enugu state had 
scored the government health facilities so low in terms of performance, and majority of 
the people would rather present to private health facilities when sick.26 Unfortunately, 
DOTS services in the State are delivered through the public health facilities because the 
private public mix (PPM) strategized by the National TB control programme,20 is yet to 
evolve in the State. The PPM strategy might have been developed because of the known 
fact that treatment of TB using orthodox medications was rampant outside DOTS services 
especially in private hospitals, as well as government hospitals (not supported by national 
TB programme), and drug stores.36 TB management in these facilities was found to be 
grossly inadequate due to the use of un-approved drug regimes, and lack of treatment 
supervision including direct observation of therapy (DOT).36 A study of 340 private 
medical practitioners in Enugu state showed that only 1.5% and 2.6% of them used the 
recommended anti-TB drug regimes and dosages respectively, while none of them 
observed the recommended treatment duration for each drug; also, patients’ follow-up 
and mechanism for tracing defaulters were largely non-existent.49 Another study of 
private medical practitioners during their annual national meeting noted that 90% of the 
respondents were involved in TB treatment (new and retreatment cases) but only 20% of 
this group adhered to the approved guidelines. It is more disturbing to note that 85 and 45 
different TB treatment regimens were used by the respondents for new and retreatment 
cases respectively.50  
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Accessibility of DOTS services: As at 2008, the State had 95 DOTS and 30 microscopy 
centers,20 serving the whole 17 local government of the State and over 3 million 
population spread over 8,727.1 square kilometres. Though the DOTS services are 
basically free, the obvious inadequate service outlets especially the microscopy centers, 
raise an accessibility concern because of the possible financial and physical difficulties of 
accessing the services. The very low number of microscopy centers may have a 
relationship with the obvious disparity between the treatment success and cure rates 
observed in the State (Table 6). Though a hospital based study from South-southern 
Nigeria had identified male sex as the only independent risk factor for TB treatment 
default,51 the inaccessibility of DOTS services was not studied and therefore remains a 
potential impediment.  
TB case mismanagement in DOTS centers: Poor history taking and the resultant 
misclassification of patients’ category, drug under-dosing, and lack of DOT were 
identified in DOTS centers in Southern Nigeria.36 These had not only contributed to 
treatment failure and development of MDR-TB but have the potential to erode the 
fledging community’s trust and confidence in the DOTS services thereby encouraging the 
already favoured alternative treatment options.   
The existence of two regimes for the continuation phase treatment of category 1 TB 
cases, where 6HE is self-administered and 4HR involves DOT,28 may encourage default 
from treatment and MDR-TB among the 6HE group.   
Government related impediments 
Though government financial commitment to TB control in Nigeria has steadily increased 
over the years, majority of the funding still come from global funds, grants and loans.6 
Nevertheless, a lot of funding gaps still exists within DOTS mainly the laboratory 
supplies and equipment,6 and the government at all levels should work towards filling the 
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gaps. The 2008 annual TB report of Nigeria subtly noted an effect of inadequate funding 
on the Enugu state TB control programme thus “… the state TB/HIV working group was 
able to identify gaps that exist in the TB & Leprosy program , the shortage of funds have 
however hindered the sittings of the committee.”20   
Finally, it was recently observed that TB drug warehousing activities in Nigeria did not 
reflect the good warehouse practice and this sub-optimal performance has the potential of 
severely compromising TB supplies if they recommendation of the study group were not 
implemented.52 The stock out of anti-TB drugs which was noted 2007 in Nigeria,6 might 
have been related to the poor warehouse practices.  
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DISCUSSION 
Trend of TB in Enugu state of Nigeria 
The sex and age patterns of new ss+ PTB found in this study are consistent with the 
known epidemiology of the disease.6;45;53 The age distribution in the study is very similar 
to the national report of 2008 with 25-34 years as the modal age group. The study’s 
findings are in line with the belief that TB is a disease of adults and that the burden of the 
disease lies more with the male sex.53 Male to female ratio among new ss+ PTB cases 
may be associated with the HIV prevalence in the general population and it has been 
shown that more female than male cases of TB are detected in countries with HIV 
prevalence of above 1%.6 Nevertheless, considering the HIV prevalence in the study area, 
it is obvious that Enugu State of Nigeria is a deviation from that general assertion. 
Furthermore, the TB burden in the State was consistently higher in females than males for 
0-14 year age group (male/female < 1). This sex pattern within that age group was not 
obvious in the national report20 but, it is consistent with the current global pattern of the 
disease.6 Currently, there are no clear explanations for the higher notification of TB in 
males than females;6 the confusion must have been compounded by the observed female 
TB case preponderance within the 0-14 year age group.  
The number of all TB cases reported annually in Enugu state showed a raising trend but 
the proportion of new ss+ PTB cases has been declining (Fig. 7). Though these trends 
were also observed in the national report,20;42 it should however stimulate further research 
especially as regards the quality of the microscopic centers within the DOTS services of 
the State and Nigeria. The prevalence of HIV infection among TB cases in this study was 
over 30% (Table 5); therefore HIV/TB co-infection can also explain the declining 
proportion of new ss+ PTB because TB patients who are HIV- positive are more likely to 
be sputum smear negative.2 
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The 4-fold increase in the detection of extra-pulmonary TB cases which started in 2005 is 
very remarkable. It is unlikely that the prevalence of this category of TB increased in the 
State rather, the notification might have been emphasized from that year by the TB 
programme – key informant interview of State programme officers would have helped to 
clarify this assumption.   
The proportion of registered TB patients that were failure or relapse cases declined from 
2006 (Table 4). This trend may suggest an improved TB management at the DOTS 
centres which may be consistent with the reported TB programme’s operational changes 
that followed the MDR-TB study in Enugu.36 These operational changes include the 
creation of awareness among national TB programme personnel on the mechanism of TB 
drug resistance and its prevention, the introduction of “dosage-friendly” FDC anti-TB 
packs, addition of the regimens 2RHEZ/4RH for category I treatment.36 However, it is 
equally likely that the number of the patients registered, did not represent the true picture 
of these categories of patients in the community. Noting that health seeking behaviour is 
related to treatment experience by patients and community among other determinants, it 
is likely that patients who relapsed or failed treatment may loose confidence in the DOTS 
services and seek alternative care from other sectors.    
Records of HIV/TB co-infection within the Enugu state TB programme apparently started 
in 2008 as suggested by the available data (Table 5). The percentage of all TB cases that 
tested positive to HIV was 32.5% and 36.2% for 2008 and 2009 respectively. Despite the 
possible effect of non-response (those not screened) which was higher in 2009, the figures 
should be considered as high. It is far higher than 27% which was the WHO estimate for 
Nigeria in 2007 and the 26.8% reported from a DOTS/GLRA supported community 
hospital from a neighbouring Imo state.6;45 Just like the HIV prevalence in the general 
population, available data (unpublished) showed that the prevalence of HIV among TB 
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cases in Enugu state was also the highest in South-eastern Nigeria However, another 
serious concern is that the proportion of TB cases (all cases and new ss+) tested for HIV 
reduced significantly in 2009 when compared to the preceding year (Table 5). Likewise, 
over 30% of all TB cases registered in 2009 were not screened for HIV despite the proven 
association and the need to initiate anti-retroviral management for co-infected patients.28 
Considering the high prevalence of HIV among those TB cases screened, the likely 
scenario is that about 30% of those not screened would be HIV-positive which implies 
that their TB treatment were not holistic since they did not benefit from anti-retroviral 
treatment. The high proportion of TB cases that were not screened for HIV, calls to 
question the quality of HIV counselling and testing (HCT) offered to TB patients in the 
State. However, if we assume an optimal HCT then, there may be the need for a change 
of counselling and testing strategy because it has been shown that refusal of certain option 
of HCT is not unusual among TB patients.54;55 The best strategy will be the “diagnostic 
HIV testing” which implies routine testing of all TB cases as recommended by the 
WHO.56 However, to address the issue of patients’ consent, the “Provider initiated HIV 
counselling and testing (PIHCT) with opt-out option”,56;57 which is currently used in 
antenatal services in Nigeria, will also be a more effective alternative to the “opt-in” 
option practised by State TB control programme.28 In the “opt-out” option, every TB 
patient receives pre-test information followed by HIV testing which s/he is free to reject 
but in “opt-in”, after the pre-test information, the patient must express consent before 
HIV testing is provided. It is believed that the introduction of the “opt-out” option to 
disease screening programme in Nigeria will provide the required “prompting” necessary 
to overcome the inertia and fear that may delay or prevent the screening of at-risk 
individuals.58;59  
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Treatment outcomes of TB in Enugu state 
Though the State’s median treatment success rate of 82% falls short of the national target 
of 85%, it is still higher than the national value of 78%,6 which suggests good 
performance by the States TB programme. However, treatment success rate for years 
2000-2003 were consistently higher than those of 2004-2008 and similar picture was also 
observed with the treatment default rate (Table 6) which may imply a reduction in 
patients’ compliance in the recent years. The reasons for the disparity should be explored 
by the State TB programme so as to improve the disease control. On the other hand, the 
disparity between treatment success rate and the cure rate may suggest inadequate 
laboratory support which appeared to have improved in 2008 when the lowest disparity 
(10%) was recorded. It is recommended that 1 microscopy center should serve 100,000 
population.6 Assuming that the State’s 2006 census figure of 3,257,298 million and the 
2010 estimate of 3,564,679 were correct, then Enugu state should have at least 37 
microscopy centers. However, it is widely held that that the 2006 census figure for the 
South-eastern zone of Nigeria was a gross and deliberate under-representation of the true 
population of the Igbo speaking States for several reasons including the attempt to reduce 
the significance of their agitation for equitable distribution of the number of States among 
the zones of the country by creation of more States from South-eastern zone. It is 
therefore very likely that the true population of Enugu state is far higher than the current 
estimates and would require a lot more microscopy centers.  
Treatment of TB in Nigeria is standardized for each patient category. Therefore, since 
under dosing and risk of monotherapy must have been minimized by the introduction of 
FDC drugs, it is possible that misclassification of category 2 patients as category 1 in the 
DOTS services as noted in Southern Nigeria,36 may be the major contributing factor to 
treatment failures in Enugu state. It takes repeated sputum microscopy at specified 
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treatment interval (annex 1) to declare a TB case as a treatment failure and during this 
“waiting period”, s/he is a risk to the community. Therefore, proper patient categorization 
should be viewed as important as quality control of microscopy centers and a mechanism 
for the routine monitoring of the performance of TB health staff should be developed and 
enforced.  
Impediments to TB control in Enugu state 
Ignorance has been identified as the major reason why TB suspects in Southern Nigeria 
do not present to DOTS centers.7 Though the referred study did not define the direction of 
ignorance but it could be derived from the context of the study’s discussion that it meant 
the ignorance as regards the existence of, and treatment capability of DOTS centers. This 
assumption is based on the fact that TB is not alien to the Igbo population of Nigeria and 
the disease is described by various names in different dialects of igbo language e-g. 
“ukwara nta”; however, the general belief about the disease’s aetiology, transmission and 
treatment differ from those of the biomedicals. This fact may be supported by a study 
from a neighbouring South-eastern state (Abia state), conducted among respondents 
randomly selected from bus terminals and markets, which showed high levels of 
knowledge of TB (including its clinical signs) that was not affected by respondents’ age 
groups, sex, occupation and educational level.60 It is argued that the poor spread of DOTS 
centers and the delivery of its services through public health facilities, which are poorly 
perceived and utilized by the communities in the State, might have contributed to the 
existing ignorance of the DOTS services. A well monitored community TB control 
programme guided by research based knowledge of the beliefs and attitude of the 
community, with full community participation in the programme planning and execution 
may help to decentralize TB control measures beyond the health facilities, improve case 
detection, reduce patient stigma, and increase access to effective TB care.46 It may also 
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help to change the belief and attitude of the people toward TB aetiology and treatment 
which will further reduce TB care seeking from drug stores and herbalists. Likewise, 
retraining of the private medical practitioners in Enugu state and their full and monitored 
involvement in TB patients’ care will enhance TB notification and care in the State. The 
community TB control programme and PPM strategies were recognized by the recent 
report and manual of the National TB programme but their implementation may still be 
evolving. A report from Kaduna state of Nigeria where PPM has been introduced by the 
State’s TB programme, has confirmed the effectiveness of the strategy - the average 
number of TB cases registered by each private health facility was approximately twice 
that of a public facility, and the treatment success rate of the private facilities was also 
higher that the public facility.61    
The WHO report showed that as at 2007, Nigeria TB programme used 6HE for 
continuation phase treatment of category 1 TB cases which suggests that the two drug 
regimens (6HE and 4HR) stated in the national manual were introduced in 2008. 
Nevertheless, the effect of the addition of the new regime (6HR) is not obvious if the 
annual proportion of treatment failure is used as an indicator of effective treatment (Table 
6). The probable explanation could still be patients’ misclassification as well as the non-
supervision (DOT) of those receiving the 6HE regime. By the introduction of such a 
guideline by the National TB programme may unknowingly be encouraging non-
supervision of anti-TB drug administration, contrary to the DOTS guideline.  
Finally, the need for improved government financial commitment to TB programme 
cannot be over-emphasized. Assuming that resources available to the TB programme are 
allocated properly and managed transparently, the report that the Enugu state TB working 
committees could not meet to discuss identified gaps, was a pointer to the real financial 
state of the State’s TB Programme. It is obvious that the TB programme in the Enugu 
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state and the whole Nigeria is driven with donor funds therefore, programme 
sustainability in future without the global funds remains a big concern.   
Study limitations 
This study is limited by the use of “cleaned” secondary data from the State’s TB 
programme and the researcher did not partake in data cleaning and the associated 
considerations. Errors could have occurred during data entry and computations, by the 
State TB programme, but were likely to be very minimal and would not have affected the 
results of the study. However, authenticity of the data is not in doubt because the State TB 
programme receives technical assistance from the WHO zonal office in the State.  
Most importantly, the disease trends identified in the study only represent cases managed 
in DOTS centers which cannot be the true situation in a population where a lot of 
treatment options exist. The assumption is in line with United Nation’s opinion that the 
TB data reported by ministries in developing countries were usually only a fraction of the 
real population figures.3 Also, due to incomplete data, the period of years reviewed for all 
study objectives was not uniform and had limited trend assessments for some variables 
such as HIV/TB co-infection.   
Furthermore, the possible impediments identified in the State’s TB programme were 
based on deductions from literatures originating form the State and similar environments 
therefore, publication bias and over-generalization from small sized studies could have 
limited the study findings. It is also recognized that the barriers identified in the study 
could not have been exhaustive and may have under-estimated or over-estimated the 
magnitude and extents of the problems.  
Nevertheless, since the study is essentially the first formal effort at articulating and 
publishing the TB burden and control barriers in the State, it is hoped that the study will 
stimulate and direct policy relevant researches in the subject area. 
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CONCLUSIONS  
Conclusions 
The study has demonstrated an increasing trend of TB cases in Enugu state of Nigeria for 
the 10 year period of 2000-20009. All TB cases and new smear negative PTB showed a 
near consistent raising trend, while that of the new ss+ PTB was fluctuating. The annual 
number of extra-pulmonary TB which increased by 4-folds in 2005 and persisted 
afterwards could be a reporting bias. Also, HIV prevalence among TB cases in Enugu 
state is high just like in the general population.  
Furthermore, the contribution of Enugu state to the TB burden of Nigeria is low and the 
new ss+ PTB treatment success rate in the State is slightly below the set target. On the 
average, the States contributes 1.77% of all TB cases and 2.10% of new ss+ PTB to the 
national annual TB register; however, a TB case registered in the State is more likely to 
be new ss+ PTB when compared to the whole nation.  
Finally, the possible threats to the effective TB control programme in the State include 
ignorance of the residents about DOTS services, lack of confidence in the public health 
care delivery system through which DOTS operates, misclassification of patients’ 
category within the DOTS system, non-compliance of private medical practitioners to the 
approved TB treatment guidelines, and inadequate funding.  
Recommendations 
In addition to the few recommendations made within the study discussion, the following 
recommendations derived from the study will enhance TB control in Enugu state of 
Nigeria.  
• The State’s TB programme should adopt the PPM which has been shown to be 
effective in Kaduna state of Nigeria. This partnership should start with the 
retraining of the private medical practitioners on the current TB management. The 
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researcher will facilitate the use of the existing quarterly continuing medical 
education (CME) programme for medical practitioners organised by the Enugu 
state chapter of the Nigerian Medical Association (NMA), as a medium of the 
retraining.   
• The national treatment guideline which also guides the State’s TB programme 
should be revised in line with the current WHO guideline.5 Most importantly, the 
use of 6HE for the continuation phase of category 1 cases should be discontinued. 
Also the “blind” commencement of re-treatment without DST should be 
minimized by developing more DST centers. These will maintained the presumed 
low MDR-TB in the country.  
• Intermittent retraining of health staff in the DOTS services on the skills of history 
taking from TB suspects so as to avoid misclassification of patients’ categories. A 
mechanism for monitoring staff performance, in this respect, should be developed 
and enforced. 
• Guideline for PTB diagnosis (Fig. 1) should be revised in line with the current 
WHO definition of new sputum smear-positive PTB because of the benefits 
already discussed. Likewise, the entry point for TB screening of cough for 2 or 
more weeks (Fig. 1) should not be applied rigidly considering the known problem 
of recall and the emerging evidence that duration of cough does not affect 
diagnoses of TB.25 Holistic review of patients’ history and clinical signs should be 
used to triage those with lower duration of cough  
• More DOTS centers and microscopy centers should be developed in the State. 
However, quality assessment (especially external) should be stepped up for the 
microscopy centers. This will ensure that poor laboratory quality is not 
contributing to the observed reduction in the proportion new ss+ PTB. 
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• Though, information alone may not guarantee change of belief and attitude but, it 
is needed before any change can occur.62 Therefore, information about the 
growing burden of the disease in the State as documented in this study should be 
fed back to the communities in the State through the existing administrative 
structures such as women meetings, and religious meetings.  
• Guided by research based knowledge of the beliefs and attitudes of the 
communities towards TB, the State’s TB programme should stimulate partnership 
with the communities in adapting and implementing the national community TB 
guideline. This will ensure that every TB suspect within a community is identified 
and properly treated. 
• Most drug store are registered under pharmacists therefore, the State’s TB 
programme should work through the Pharmaceutical Society of Nigeria to 
discourage treatment of chronic cough at the drug stores by educating them on the 
availability and effectiveness of DOTS centers in the State 
• Health education in primary and secondary schools should be re-energized and 
used to disseminate information about TB burden, transmission and the available 
treatment sites to the households 
• The State TB programme should improve on its record keeping and data storage. 
Use of effective and updated anti-virus for its computers should be encouraged 
• In the face of serious financial difficulties, very important committee meetings of 
the State’s TB programme could be financed by indigenous organization and 
charity bodies if adequately mobilized.  
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ANNEXES  
Annex 1: Follow up of PTB patients in Nigeria using sputum smear microscopy28 
A: Intensive treatment phase 
 
 
B: Continuation treatment phase (5th month) 
 
 
 
 
 
 
At 5 months:  
Take sputum for 
examination one week 
prior to the end of 5
th
 
month 
Two results negative 
Two results positive or 
scanty 
At least one positive or 
scanty result 
Continue treatment 
If on Cat 1: declare failure, 
register again and start 
Category 2 regimen  
If on Cat 2: continue.  
Repeat two sputum smear 
examinations after two weeks 
Two negative One or two positive or scanty 
Continue If on Cat 1: declare failure, register 
again and start Category 2 regimen  
If on Cat 2: send to referral centre* 
 
At 2/3 months: 
Take 2 sputum specimens 
about one week prior to 
completion of intensive 
phase 
If one or two 
positive results (sc, 
+) 
If two samples are 
negative 
Add 1 month of 
intensive phase  
Start continuation 
phase 
Repeat smear examination at 3 months (Cat 
1) or 4 months (Cat 2). Then start 
continuation phase. 
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C: Continuation treatment phase (6/7th month) 
 
  
 
At 6/7 months:  
Take sputum for 
examination one week 
prior to the end of 
6/7
th
 month 
Two results negative 
Two results positive or 
scanty 
At least one positive or 
scanty result 
Continue treatment and declare cured 
If on Cat 1: declare failure, register again 
and start Category 2 regimen  
If on Cat 2: declare failure, continue to 
the end of 8 months and send to referral 
centre* 
Repeat two sputum smear examinations 
after two weeks 
Two negative One or two positive or scanty 
Continue 
treatment and 
declare cured 
If on Cat 1: declare failure, register 
again and start Category 2 regimen  
If on Cat 2: declare failure, continue 
to the end of 8 months and send to 
referral centre* 
